Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors.
暂无分享,去创建一个
R. Jain | S. Ramanujan | G. Koenig | T. Padera | B. Stoll
[1] I. Tannock,et al. THE RELATION BETWEEN CELL PROLIFERATION AND THE VASCULAR SYSTEM IN A TRANSPLANTED MOUSE MAMMARY TUMOUR , 2007 .
[2] E. Gillette,et al. Morphometric analyses of the microvasculature of tumors during growth and after x‐irradiation , 1974, Cancer.
[3] P. Vaupel. Hypoxia in neoplastic tissue. , 1977, Microvascular research.
[4] M Intaglietta,et al. Tissue perfusion inhomogeneity during early tumor growth in rats. , 1979, Journal of the National Cancer Institute.
[5] R. Sutherland,et al. Oxygen diffusion distance and development of necrosis in multicell spheroids. , 1979, Radiation research.
[6] L. Woolner,et al. Occult papillary carcinoma of the thyroid. , 1980, Archives of surgery.
[7] C. Prowse,et al. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. , 1983, Thrombosis research.
[8] R K Jain,et al. Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.
[9] Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. , 1985, Thrombosis research.
[10] K. Franssila,et al. Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.
[11] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[12] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[13] R K Jain,et al. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Wagner,et al. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half‐life , 1989, Journal of cellular physiology.
[15] Peter J. Polverini,et al. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.
[16] R T Prehn,et al. The inhibition of tumor growth by tumor mass. , 1991, Cancer research.
[17] N. Mayr,et al. Morphometric studies in intraductal breast carcinoma using computerized image analysis , 1991, Cancer.
[18] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[19] H. Lyng,et al. Blood flow in six human melanoma xenograft lines with different growth characteristics. , 1992, Cancer research.
[20] R. Prehn. Two competing influences that may explain concomitant tumor resistance. , 1993, Cancer research.
[21] E. Edelman,et al. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Delmas,et al. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.
[23] A. Uchida,et al. Serum concentrations of basic fibroblast growth factor in breast cancer. , 1994, Clinical chemistry.
[24] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[25] P. Hahnfeldt,et al. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. , 1994, Cancer research.
[26] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[27] R. Demicheli,et al. Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.
[28] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[29] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[30] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[31] S. Soker,et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.
[32] S. Koscielny,et al. Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.
[33] K Groebe,et al. On the relation between size of necrosis and diameter of tumor spheroids. , 1996, International journal of radiation oncology, biology, physics.
[34] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[35] M. Toi,et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[37] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[38] R K Jain,et al. Direct in vivo measurement of targeted binding in a human tumor xenograft. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[39] Paolo A. Netti,et al. Solid stress inhibits the growth of multicellular tumor spheroids , 1997, Nature Biotechnology.
[40] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[41] S. Szabó,et al. The diagnostic and prognostic value of tumor angiogenesis. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.
[42] R. Jain,et al. Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.
[43] R K Jain,et al. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. , 1998, Cancer research.
[44] B. Zetter,et al. Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.
[45] S. Ménard,et al. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] W. Deen. Analysis Of Transport Phenomena , 1998 .
[47] R. Timpl,et al. Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin , 1998, The EMBO journal.
[48] J. Folkman,et al. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. , 1998, Archives of dermatology.
[49] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[50] N. Nelson. Angiogenesis research is on fast forward. , 1999, Journal of the National Cancer Institute.
[51] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[52] R K Jain,et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.
[53] R. Jain. Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.
[54] Ridgway Pf. Tumours : wounds that do not heal. , 2002 .